ProfileGDS5678 / 1444273_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 48% 40% 49% 53% 53% 47% 58% 50% 60% 49% 47% 51% 62% 47% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.186848
GSM967853U87-EV human glioblastoma xenograft - Control 22.9158840
GSM967854U87-EV human glioblastoma xenograft - Control 33.1809249
GSM967855U87-EV human glioblastoma xenograft - Control 43.2389753
GSM967856U87-EV human glioblastoma xenograft - Control 53.2362253
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.2129747
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.5916458
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.1806950
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.6005260
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.1463849
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.100347
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.1801751
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.7182462
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.1049147